Courtesy : A news clip from The Guardian , UK 26th December2024.
Can any one dare to stop this prescription medication with significant metabolic side effects ,being flashed in the New York bill board ?
Semaglutide is a GLP 1 agonist, (Glucagon like peptide) primarily used in diabetes where it competes with glucagon and modulates its adverse action. By some unknown mechanism this drug reduces body weight. The consequences of which is not clear. Meanwhile this drug got cleared as a magic bullet , as a weekly shot injection in obesity .We don’t yet know the long term effects of this drug. But, already it is promoted in social media, (as if it is a Pepsi or Coke) bypassing the physicians. It is a new low in pharma marketing strategies. (No one bothers, rather, no one wants to bother.)
Final message
The primary issue here is, not about the quick buck of profit, these companies want to make. It is about the potential Injury it can cause to patient’s ,(rather, healthy peoples’)metabolic landscape.
Dr.S.Venkatesan MD 